JP2008531631A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008531631A5 JP2008531631A5 JP2007557422A JP2007557422A JP2008531631A5 JP 2008531631 A5 JP2008531631 A5 JP 2008531631A5 JP 2007557422 A JP2007557422 A JP 2007557422A JP 2007557422 A JP2007557422 A JP 2007557422A JP 2008531631 A5 JP2008531631 A5 JP 2008531631A5
- Authority
- JP
- Japan
- Prior art keywords
- epac
- group
- directed
- pharmaceutical composition
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65770705P | 2005-03-03 | 2005-03-03 | |
| PCT/EP2006/001903 WO2006094703A1 (en) | 2005-03-03 | 2006-03-02 | Use of an antagonist of epac for treating human cardiac hypertrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008531631A JP2008531631A (ja) | 2008-08-14 |
| JP2008531631A5 true JP2008531631A5 (enExample) | 2009-04-16 |
Family
ID=36283051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007557422A Withdrawn JP2008531631A (ja) | 2005-03-03 | 2006-03-02 | ヒト心臓肥大症を治療するためのｅｐａｃのアンタゴニストの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090169540A1 (enExample) |
| EP (1) | EP1853316A1 (enExample) |
| JP (1) | JP2008531631A (enExample) |
| CA (1) | CA2599783A1 (enExample) |
| WO (1) | WO2006094703A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007095278A2 (en) * | 2006-02-15 | 2007-08-23 | The Regents Of The University Of Michigan | Screening assays for antagonists and analyses of cardiac hypertrophy |
| GB0815315D0 (en) * | 2008-08-21 | 2008-09-24 | Univ Leiden | Organ protection |
| US20110060029A1 (en) * | 2009-04-08 | 2011-03-10 | Kosaku Iwatsubo | Method of treating cancer by modulating epac |
| CA2864356A1 (en) | 2012-02-10 | 2013-08-15 | The Board Of Regents Of The University Of Texas System | Modulators of exchange proteins directly activated by camp (epacs) |
| WO2014053315A1 (en) * | 2012-10-02 | 2014-04-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Tetrahydroquinoline derivatives and their use as epac inhibitors |
| US20170079970A1 (en) * | 2014-03-21 | 2017-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale | Tetrahydroquinoline derivatives and their use as epac1 inhibitors for the treatment of myocardial infarction injury |
| US9737512B2 (en) | 2015-03-11 | 2017-08-22 | The Board Of Regents Of The University Of Texas System | Methods and compositions for treating chronic pain |
| JP6978774B2 (ja) * | 2015-11-06 | 2021-12-08 | 国立大学法人 熊本大学 | 心不全の予防又は治療のための医薬組成物 |
| WO2020064597A1 (en) * | 2018-09-24 | 2020-04-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of epac1 activators for the treatment of chronic kidney diseases |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1107789T3 (da) * | 1998-08-24 | 2008-11-03 | Univ Leland Stanford Junior | Sammensætninger og metoder til beskyttelse af organer, væv og celler mod beskadigelse formidlet af immunsystemet |
| WO2000024768A2 (en) * | 1998-10-23 | 2000-05-04 | Massachusetts Institute Of Technology | Genes integrating signal transduction pathways |
-
2006
- 2006-03-02 US US11/885,452 patent/US20090169540A1/en not_active Abandoned
- 2006-03-02 JP JP2007557422A patent/JP2008531631A/ja not_active Withdrawn
- 2006-03-02 EP EP06707377A patent/EP1853316A1/en not_active Withdrawn
- 2006-03-02 WO PCT/EP2006/001903 patent/WO2006094703A1/en not_active Ceased
- 2006-03-02 CA CA002599783A patent/CA2599783A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Malakar et al. | A review on coronary artery disease, its risk factors, and therapeutics | |
| Yang et al. | A pathway and network review on beta-adrenoceptor signaling and beta blockers in cardiac remodeling | |
| Leonard et al. | VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury | |
| Pan et al. | The role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies | |
| Rengo et al. | Myocardial β2‐adrenoceptor gene delivery promotes coordinated cardiac adaptive remodelling and angiogenesis in heart failure | |
| Kim et al. | Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension | |
| Behmenburg et al. | Impact of mitochondrial Ca2+-sensitive potassium (mBKCa) channels in sildenafil-induced cardioprotection in rats | |
| Emter et al. | Low-intensity aerobic interval training attenuates pathological left ventricular remodeling and mitochondrial dysfunction in aortic-banded miniature swine | |
| Wright et al. | A class of their own: exploring the nondeacetylase roles of class IIa HDACs in cardiovascular disease | |
| JP2007505158A (ja) | 心肥大および心不全の処置としてのプロテインキナーゼＣ−μ（ＰＫＤ）の阻害 | |
| Wang et al. | Type 2 cGMP-dependent protein kinase regulates homeostasis by blocking c-Jun N-terminal kinase in the colon epithelium | |
| US11938129B2 (en) | Methods and compositions for the treatment of vascular disease | |
| Kennel et al. | The PHD1 oxygen sensor in health and disease | |
| JP2008531631A5 (enExample) | ||
| Rinaldi et al. | Effects of sildenafil on the gastrocnemius and cardiac muscles of rats in a model of prolonged moderate exercise training | |
| Gopallawa et al. | Angiotensin-(1–7)/mas inhibits apoptosis in alveolar epithelial cells through upregulation of MAP kinase phosphatase-2 | |
| Deleeuw et al. | An overview of investigational and experimental drug treatment strategies for Marfan syndrome | |
| WO2020095971A1 (ja) | 老化細胞を除去する方法、および老化細胞の調製方法 | |
| TWI430812B (zh) | 調控細胞中ｃａｇ擴張基因之基因產物與其聚集的方法及其應用 | |
| Dai et al. | Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease | |
| Chen et al. | Src kinase pathway is involved in NFAT5-mediated S100A4 induction by hyperosmotic stress in colon cancer cells | |
| Yang et al. | Correlation of increased hippocampal Sumo3 with spatial learning ability in old C57BL/6 mice | |
| Jin et al. | A chymase inhibitory RNA aptamer improves cardiac function and survival after myocardial infarction | |
| Chen et al. | Role of ATG7-dependent non-autophagic pathway in angiogenesis | |
| US20080248032A1 (en) | Compositions and methods for protection against cardiac and/or central nervous system tissue injury by inhibiting sphingosine-1-phosphate lyase |